Johnson & Johnson
JNJ
$270.24
+1.07%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Following the 2023 divestiture of its consumer health business (Kenvue), the company has sharpened its focus on high-growth areas like oncology, immunology, and neurology, positioning itself as a leader in both drug development and medical technology. The current investor narrative centers on the company's robust pipeline, including the recent FDA clearance of its surgical robot, a proposed talc settlement that removes a major legal overhang, and management's ambitious target of $100 billion in revenue. With a 64th consecutive dividend increase and strong earnings momentum, JNJ is being viewed as a defensive growth play, though its elevated valuation has sparked debate about whether the stock is overextended after a significant rally.…
JNJ
Johnson & Johnson
$270.24
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating: Buy. Johnson & Johnson offers a rare combination of defensive stability and growth potential, with a consensus 'Buy' rating and an average target price of $272.50, implying 4.7% upside. The thesis is anchored on accelerating revenue growth (9.9% YoY), strong profitability (net margin 28.5% TTM), and a robust pipeline that supports long-term expansion.
Sign up to view all
JNJ 12-Month Price Forecast
The AI model assesses JNJ as a bullish opportunity, given its strong fundamental momentum, attractive valuation on a PEG basis, and positive analyst sentiment. The main risks are valuation premium and litigation, but the company's defensive characteristics and growth pipeline provide a favorable risk-reward. An upgrade to high confidence would occur if revenue growth sustains above 10% and talc settlement is finalized; a downgrade would occur if margins compress significantly or litigation costs spiral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $272.50 and implied upside of +0.8% versus the current price.
Average Target
$272.50
0 analysts
Implied Upside
+0.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $305
Analyst target range
The stock is covered by 22 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.91 (where 1 is Strong Buy and 5 is Sell). The average target price is $272.50, implying an upside of 4.7% from the current price of $260.35. The distribution is bullish, with 15 Buy ratings, 5 Hold ratings, and 2 Sell ratings, indicating that the Street is largely optimistic about JNJ's prospects. The target price range is $190.00 (low) to $305.00 (high), with the high target suggesting a 17.2% upside, likely reflecting optimism about the surgical robot and pipeline, while the low target implies a 27.0% downside, possibly pricing in talc litigation risks or competitive pressures. Recent ratings actions have been mostly positive, with RBC Capital and TD Cowen reiterating Buy ratings in July 2026, and Leerink Partners upgrading from Market Perform to Outperform in May 2026, indicating a constructive sentiment shift. The wide spread between the low and high targets (115 points) reflects significant uncertainty around the talc settlement and pipeline execution, but the overall bullish consensus suggests that analysts see more upside than downside.
Bulls vs Bears: JNJ Investment Factors
Johnson & Johnson presents a compelling bull case with accelerating revenue growth, robust profitability, a strong balance sheet, and a promising pipeline. The bear case centers on valuation concerns, margin compression, and lingering talc litigation. Currently, the bull case has stronger evidence, as the company's fundamental momentum and strategic catalysts outweigh near-term valuation risks. The most critical tension is whether the company can sustain its high growth rates and margin expansion to justify its premium valuation, or if competitive pressures and legal costs will erode its financial performance.
Bullish
- Robust Revenue Growth: Q1 2026 revenue grew 9.9% YoY to $24.06B, driven by strong performance in Innovative Medicine ($15.43B) and MedTech ($8.64B). This marks the fourth consecutive quarter of accelerating growth, from $21.89B in Q1 2025.
- High Profitability and Margins: Gross margin stands at 71.5% and operating margin at 26.6%, with net margin of 21.8% in Q1 2026. ROE is an impressive 32.9%, reflecting efficient capital allocation and a strong competitive moat.
- Strong Balance Sheet and Cash Flow: Debt-to-equity is a conservative 0.59, and free cash flow for TTM is $17.8B, providing ample coverage for dividends and strategic investments. Interest coverage of 23.5x indicates minimal financial risk.
- Pipeline and Innovation Momentum: Recent FDA clearance for its surgical robot and a proposed talc settlement remove major overhangs, while management targets $100B in revenue. R&D spending of $3.53B in Q1 2026 supports long-term growth.
Bearish
- Elevated Valuation vs. Peers: Trailing PE of 18.8x is a 23.7% premium to the industry average of 15.2x. While justified by superior margins, this premium could compress if growth decelerates or market sentiment shifts.
- Forward PE Higher Than Trailing: Forward PE of 21.2x exceeds trailing PE of 18.8x, implying the market expects earnings to decline. This unusual gap suggests near-term headwinds from increased R&D spending or legal costs.
- Talc Litigation Overhang: Despite a proposed settlement, legal risks persist. The low analyst target of $190.00 implies a 27.0% downside, likely pricing in adverse litigation outcomes or competitive pressures.
- Margin Compression: Operating margin declined from 28.8% in Q1 2025 to 26.6% in Q1 2026, and net margin fell from 50.2% (one-time gain) to 21.8%. Increased R&D spending and potential legal costs could pressure margins further.
JNJ Technical Analysis
Johnson & Johnson's stock is in a strong uptrend, with a 1-year price change of +49.0% and a current price of $260.35, which sits at 94.7% of its 52-week range (low of $173.33, high of $274.90). The stock has recovered sharply from its April 2026 lows near $224, and the recent breakout above the $255 level in late June signals renewed bullish momentum. Trading near the upper end of its range suggests the market is rewarding the company's fundamental progress, but it also raises the risk of short-term overextension, especially given the stock's beta of just 0.23, which indicates lower volatility than the broader market.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$173-$276
Price range past year
Annual Return
+51.0%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +5.7% | +2.5% |
| 3m | +15.3% | +2.7% |
| 6m | +11.4% | +11.1% |
| 1y | +51.0% | +20.5% |
| ytd | +30.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth has accelerated, with Q1 2026 revenue of $24.06 billion, up 9.9% year-over-year, driven by strong performance in Innovative Medicine ($15.43 billion) and MedTech ($8.64 billion). The company has consistently grown revenue over the past year, from $21.89 billion in Q1 2025 to $24.06 billion in Q1 2026, reflecting robust demand for its pharmaceutical portfolio and medical devices. Net income of $5.24 billion in Q1 2026 represents a net margin of 21.8%, down from the unusually high 50.2% in Q1 2025 (which included a one-time gain), but still solid. Gross margin remains strong at 71.5%, and operating margin of 26.6% is healthy, though slightly below the 28.8% reported in Q1 2025, indicating modest margin compression due to increased R&D spending ($3.53 billion in Q1 2026). The balance sheet is well-capitalized with a debt-to-equity ratio of 0.59 and a current ratio of 1.03, while free cash flow for the trailing twelve months stands at $17.8 billion, providing ample coverage for dividends and strategic investments. ROE is an impressive 32.9%, reflecting efficient use of equity, and the company's interest coverage ratio of 23.5x indicates low financial risk.
Quarterly Revenue
$24.1B
2026-03
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
71.5%
Latest Quarter
Free Cash Flow
$17.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given that net income is positive, the PE ratio is the primary valuation metric. The trailing PE is 18.8x, while the forward PE is 21.2x, implying that the market expects earnings to decline slightly over the next year, which is unusual for a growth-oriented company. This gap suggests that the market is pricing in near-term headwinds, possibly from increased R&D spending or legal costs, but the PEG ratio of 0.21 indicates that the stock is undervalued relative to its expected earnings growth. Compared to the industry average, JNJ's PE of 18.8x is at a premium to the sector's average of 15.2x, a 23.7% premium, which is justified by its superior profitability (net margin of 28.5% vs. industry average of 12.3%) and strong competitive position. Historically, the stock's PE has ranged from 9.1x (Q1 2025) to 36.2x (Q3 2024), and the current 18.8x is near the lower end of its 5-year band, suggesting that the stock is not overvalued relative to its own history, despite the recent rally.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a forward PE (21.2x) higher than trailing (18.8x), implying expected earnings decline, and a debt-to-equity ratio of 0.59, which is manageable but could increase if legal settlements are larger than anticipated. Free cash flow of $17.8B provides a cushion, but margin compression (operating margin down from 28.8% to 26.6% YoY) could persist due to elevated R&D spending ($3.53B in Q1 2026) and potential legal costs. Revenue concentration in Innovative Medicine (64% of total) exposes the company to patent cliffs and regulatory pricing pressures in the pharmaceutical segment.